The following is the summary of “Effect of Latanoprost on Choroidal Vascularity Index in Glaucoma and Ocular Hypertension” published in the December 2022 issue of Glaucoma by Cakir, et al.

One such metric is the choroidal vasculature index (CVI), which was recently developed. Insight into the etiology of latanoprost’s posterior segment adverse effects, such as cystoid macular edema and central serous choroidopathy, can be gained from the reduction in CVI that follows its use. The goal of this research is to analyze the effects of latanoprost on the central visual field (CVI), total choroidal area (TCA), stromal area (SA), luminal area (LA), and choroidal thickness (CT) in patients with primary open-angle glaucoma and ocular hypertension.

Patients with newly diagnosed primary open-angle glaucoma or ocular hypertension who had never previously been treated with antiglaucoma medication were included. Latanoprost 0.005% was administered orally once daily. Before beginning latanoprost treatment, scans were acquired in the first and third months using spectral-domain optical coherence tomography’s enhanced depth imaging mode. The scans were used to determine the CT thickness in the fovea, the central visual acuity, the temporal central acuity, the lateral central acuity, and the superior oblique angle, as well as the four quadrants of the peripapillary region. It was determined by examining the data from 36 eyes of 18 patients. The CT scans taken under the eye’s cornea showed a notable rise in volume under the macula (P=0.007). First and third-month mean TCA (P=0.008) and SA (P<0.001) were higher than the baseline in the submacular regions. 

The first and third months had significantly decreased mean CVIs (P<0.001). Mean TCA and SA increased in the temporal (P=0.001) and inferior (P=0.028) quadrants of the periphery, while mean CVI decreased in the temporal (P=0.027) and inferior (P=0.003) quadrants. The decline in intraocular pressure rate was negatively correlated with central visual acuity (CVI) in the macula. The CVI was dramatically reduced in newly treated individuals with glaucoma or ocular hypertension after several months of latanoprost usage, along with other changes to the choroid. These results have the potential to elucidate how prostaglandins influence the retina and the back of the eye.